Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.36 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.35 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.34 |
| ▸ | PRKCA | P17252 | 2/20 | 0.34 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.34 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.34 |
| ▸ | PRKCB | P05771 | 1/20 | 0.34 |
| ▸ | PRKCH | P24723 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20012046 | 0.88 | PRKCA (0.40) | ROCK2PRKCAPRKCDPRKD1 | |
| SCHEMBL19995615 | 0.87 | KCNH2 (0.41) | PRKCAPRKCDPRKD1ITGA2B | |
| SCHEMBL20011905 | 0.86 | ROCK2 (0.45) | ADRB2NCF1PLD1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL21853879 | 0.86 | KCNH2 (0.40) | PRKCAPRKCDPRKD1ITGA2B | |
| Hydrochloric Acid SCHEMBL19995676 | 0.85 | ROCK2 (0.44) | ADRB2NCF1PLD1ALDH1A1MAPT | |
| SCHEMBL19996025 | 0.85 | RPS6KA3 (0.35) | ADRB2NCF1PLD1PRKCAPRKCD | |
| SCHEMBL20011985 | 0.84 | GRIA1 (0.37) | ALDH1A1MAPTHPGDALOX15HSD17B10 | |
| Hydrochloric Acid SCHEMBL21853844 | 0.84 | RPS6KA3 (0.34) | — | |
| SCHEMBL20011892 | 0.83 | LATS1 (0.45) | ALDH1A1MAPTHPGDALOX15HSD17B10 | |
| SCHEMBL20012004 | 0.82 | ROCK2 (0.51) | ADRB2NCF1PLD1ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110036006-B | Preparation and use of pyrimidinone derivatives | 癌症研究科技有限公司 | 2022-12-13 | — | — | CN | claimed |
| US-10919896-B2 | Preparation and uses of pyrimidinone derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-02-16 | — | — | US | claimed |
| EP-3515903-B1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES | CANCER RESEARCH TECH LTD (GB) | 2020-10-21 | — | — | EP | claimed |
| US-20200123157-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVE | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. | 2020-04-23 | — | — | US | claimed |
| CN-110036006-B | Preparation and use of pyrimidinone derivatives | 癌症研究科技有限公司 | 2022-12-13 | — | — | CN | disclosed |
| US-10919896-B2 | Preparation and uses of pyrimidinone derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-02-16 | — | — | US | disclosed |
| US-10919896-B2 | Preparation and uses of pyrimidinone derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-02-16 | — | — | US | disclosed |
| EP-3515903-B1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES | CANCER RESEARCH TECH LTD (GB) | 2020-10-21 | — | — | EP | disclosed |
| EP-3515903-B1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES | CANCER RESEARCH TECH LTD (GB) | 2020-10-21 | — | — | EP | disclosed |
| US-20200123157-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVE | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. | 2020-04-23 | — | — | US | disclosed |
| US-20200123157-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVE | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. | 2020-04-23 | — | — | US | disclosed |
| WO-2018055402-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919896-B2 | Preparation and uses of pyrimidinone derivatives | CDC7, CDK7, CDK17 | ADRB2 4207/4885NCF1 975/4885PLD1 805/4885 |
| US-20200123157-A1 | PREPARATION AND USES OF PYRIMIDINONE DERIVATIVE | CDC7, CDK7, CDK17 | ADRB2 4259/4885NCF1 956/4885PLD1 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.